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Chapter 57.4 Personalized 
management of atrial fibrillation
Larissa Fabritz, Eduard Guasch, Moritz Sinner,  
and Paulus Kirchhof
Summary
◆ Clinical management of patients with atrial fibrillation 
(AF) today is merely guided by stroke risk, AF pattern, 
drug safety, and patient- reported symptoms.
◆ To facilitate more personalized treatment of patients 
with AF, clinical markers reflecting the major causes of 
AF in patients need to be validated and used in practice.
◆ More personalized and more integrated care will improve 
outcomes in patients with AF.
Introduction
Atrial fibrillation (AF) is a major cause of cardiovascular morbidity 
and mortality, despite excellent efforts to improve management 
OUP UNCORRECTED PROOF – FIRSTPROOFS, Sat Jun 23 2018, NEWGEN
med-9780198784906-Sec-57.indd   9 23-Jun-18   5:36:13 AM
SECTION 57 precision medicine10
of patients suffering from the condition.1 While many strokes 
can be prevented by oral anticoagulants, heart failure and sud-
den death remain common, and unplanned hospitalizations 
contribute further to the burden of AF to affected patients and 
society.2 It is well established that different mechanisms cause the 
arrhythmia in different models of AF,3 ranging from a genomic 
predisposition, altered calcium handling, and oxidative stress, to 
atrial infiltration with fat and fibrous tissue. A similar diversity 
of the drivers for AF can be found in patients,4 and several addi-
tional ‘vicious circles’ contribute to perpetuation of AF (Figure 
57.4.1). Identification of the major drivers of AF in different 
patients has the potential to improve AF outcomes through per-
sonalized interventions, particularly recurrent AF, as exempli-
fied by the therapeutic success of prevention of AF recurrence by 
intensive weight reduction in obese patients with AF.5, 6
Current state of atrial fibrillation  
management
Clinical risk scores already guide treatment decisions in patients 
with AF, for example, the CHA2DS2VASc score that is used to 
guide oral anticoagulation in AF patients.7 Other treatment areas 
are much less established, for example, the optimal type and 
intensity of ventricular rate control8– 10 or the optimal rhythm 
control treatment.11 Even less is currently known about the best 
methods to prevent the predicted rise in AF prevalence and inci-
dence.12 Understanding the major drivers causing AF in different 
patient populations, for example, those with AF and heart failure, 
those with AF due to a genetic predisposition, those with AF and 
hypertension, those with AF and chronic kidney disease, or those 
with AF and obesity or metabolic defects, is required to discern 
specific targets for personalized prevention and therapy of the 
arrhythmia.4
recent advances underpinning personalized 
prevention and management of patients 
with atrial fibrillation
We have good knowledge of the vicious circles maintaining AF 
once it has been initiated (Figure 57.4.1). Our knowledge of the 
major drivers of AF, including drivers of AF that act prior to 
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Figure 57.4.1 Different vicious circles driving and maintaining atrial fibrillation.
Reproduced with permission from Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 
2011;91(1):265– 325. https:// doi.org/ 10.1152/ physrev.00031.2009. Copyright © 2011 The American Physiological Society.
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the first episode, has advanced in the last decades. To give a few 
examples:
◆ The first genome- wide association study of AF was published a 
decade ago in 2007,13 suggesting for the first time an important 
link between (left) atrial transcription factors such as PITX2 
and AF. Further work inspired by this initial observation has 
delineated a role for such transcription factors for atrial func-
tion and genesis of AF.14– 16
◆ In addition to the known effects of atrial dilatation and pressure 
overload on cellular calcium handling and metabolic homeo-
stasis, recent work has identified relevant roles for subcellular 
domains for atrial function.17
Mechanisms causing AF
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Figure 57.4.2 (a) A road map for a new taxonomy of patients with atrial fibrillation (AF). (b) Interdisciplinary approaches to identify different types of 
patients with atrial fibrillation based on the major drivers causing the arrhythmia.
Panel (a) is reproduced with permission from Fabritz L, et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin 
personalized prevention and treatment. Nat Rev Cardiol 2016;13(4):230– 7. doi:10.1038/ nrcardio.2015.194. Copyright © 2017 Macmillan Publishers Limited, part of Springer Nature. 
Panel (b) with permission from Kirchhof P, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/ European 
Heart Rhythm Association consensus conference. Europace 2016;18(1):37– 50. https:// doi.org/ 10.1093/ europace/ euv304. Copyright © 2015 Oxford University Press.
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◆ Atrial fibroblasts,18 fat cells,19 and oxidative stress20 have been 
shown to modulate atrial cardiomyocyte function to create an 
arrhythmogenic substrate.
◆ Yet other mechanisms cause AF in patients with inherited 
arrhythmogenic conditions and inherited cardiomyopathies.3
Thus, we have an approximate understanding of the potential 
drivers for AF in different patients, but we have yet to translate 
this into stratified approaches to the prevention of AF and man-
agement of individual patients with AF.
Development of personalized atrial fibrillation 
prevention and management
The pathophysiological heterogeneity driving AF and most 
likely its complications has led to a demand for a new dis-
ease taxonomy that better reflects disease mechanisms in AF.4 
Genomic and biomedical differences could guide such a tax-
onomy as well as different social contexts and behavioural pat-
terns (Figure  57.4.2a). It is necessary to describe and classify 
these drivers in patients, and define a valid taxonomy of dif-
ferent pathophysiological types of AF to underpin the develop-
ment of stratified approaches to AF management. This requires 
flexible thinking and interdisciplinary interaction between 
scientists, clinicians, regulators, funders, and industry part-
ners. Markers for such different types of AF could, for exam-
ple, be derived from clinical parameters, careful analysis of the 
electrocardiogram, assessment of blood and urine, and others 
(Figure  57.4.2b). Importantly, the scientific method used to 
generate and validate knowledge, that is, identification of novel 
disease drivers and therapeutic targets, and experimental inter-
ventions to demonstrate their physiological relevance, through 
controlled, randomized clinical trials in patient subpopulations 
harbouring the identified disease drivers, needs to be upheld to 
allow robust development of such approaches.
Conclusion
Patients with AF are in need of personalized approaches to pre-
vention and therapy. Interdisciplinary cooperation between 
scientists, clinicians and other healthcare providers, regula-
tors, industry government agencies, and charities is required, 
to unleash the potential of personalized management of AF in 
the future, starting with the development of a new taxonomy of 
AF based on the major mechanisms causing the arrhythmia in 
different patients, allowing the identification of novel treatment 
targets and evaluation of personalized interventions reversing 
these drivers in clinical trials.
Online resources
% For full references and multimedia materials please visit the 
online version of the book (http:// www.oup.com/ esccardiomed).
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